A panel of independent experts voted narrowly in favour of continuing to require cardiovascular outcomes data for new diabetes drugs, but urged relaxation and simplification of the safety assessment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future
BMC Medicine Open Access 26 February 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on. Nat Rev Drug Discov 17, 850–851 (2018). https://doi.org/10.1038/nrd.2018.206
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.206